ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease

September 13, 2017 07:30 ET | Source: ProMIS Neurosciences Inc. ProMIS Neurosciences Inc.

TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK

Recommended Reading

August 13, 2026 16:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases...
Read More
August 03, 2026 16:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage...
Read More